China Biotech Licensing Wave: What It Means for Western BD Teams

In 2023, Chinese biotechs signed over $50 billion in total deal value with Western pharma companies. By mid-2024, that pace had accelerated further. Companies like BeiGene, Legend Biotech, and Zymeworks-adjacent Chinese firms were commanding upfront payments that would have been unthinkable five years earlier.

For Western BD teams, this wave represents both opportunity and complexity. Chinese biotech pipelines contain genuinely differentiated molecules – particularly in oncology, immunology, and cell therapy. At the same time, the licensing structures, IP considerations, and due diligence requirements differ substantially from traditional Western biotech deals.

This article explains why the wave is happening, what Western BD teams need to evaluate, and how deal structures are adapting.

The Problem: Western BD Teams Are Not Equipped for China-Origin Deals

Most Western BD teams were built to evaluate US and European biotech assets. Their due diligence frameworks, valuation models, and risk assessment criteria assume Western regulatory systems, IP protections, and clinical trial standards.

According to Nature Reviews Drug Discovery, China-origin molecules represented over 20% of global licensing deals in 2024, up from less than 5% in 2018.

Three specific gaps create problems:

IP assessment complexity. Chinese patent filings follow different timelines and examination standards. Western BD teams struggle to assess the strength of China-origin IP without specialized expertise.

Clinical data interpretation. Many Chinese biotech clinical trials are conducted primarily in Chinese patient populations. Extrapolating efficacy and safety data to Western populations requires careful analysis.

Regulatory pathway uncertainty. An asset with Chinese NMPA approval or clinical data may still face significant FDA or EMA requirements, including bridging studies.

The Insight: Why Chinese Biotechs Are Out-Licensing Now

The real insight: The China licensing wave is not primarily about cost arbitrage. It is about access to differentiated science. Chinese biotechs have developed genuinely novel molecules – particularly bispecific antibodies, ADCs, and cell therapies – that fill gaps in Western pharma pipelines. The funding winter in China is accelerating out-licensing, but the underlying value is real.

Deal Volume and Value Trend

Decision Intelligence: What to Evaluate in China-Origin Deals

The Solution: Adapting Your BD Process

Western BD teams evaluating China-origin assets should add three steps to their standard process.

Step 1: Engage China-experienced IP counsel. Standard patent diligence is not sufficient. You need attorneys who understand Chinese patent prosecution and can assess cross-border IP strength.

Step 2: Evaluate clinical data translatability. Work with regulatory consultants to assess whether China-generated clinical data will satisfy FDA/EMA requirements or if additional studies are needed.

Step 3: Assess supply chain resilience. Map the manufacturing chain. Identify whether the CDMO or drug substance manufacturing can be transferred or duplicated outside China if needed.

The Value: What Getting China Deals Right Delivers

Pipeline acceleration. China-origin clinical-stage assets can be 2-3 years ahead of comparable Western programs at similar valuations.

Differentiated molecules. Access to novel bispecifics, next-gen ADCs, and cell therapies not available from Western biotechs.

Competitive advantage. BD teams that can confidently evaluate China deals access a deal pool that less-prepared competitors avoid.

Example: A Successful China In-License

A mid-size US pharma with an oncology focus evaluated a bispecific antibody from a Shanghai-based biotech. The molecule had completed Phase 1/2 in China with strong efficacy signals. The BD team initially hesitated due to single-ethnic clinical data.

After engaging specialized IP counsel and regulatory consultants, they confirmed the PCT patent family was strong, the clinical data supported a US IND, and a bridging study with 50-100 US patients would likely suffice for FDA. They structured the deal with a $30M upfront, $400M in milestones, and 8-12% royalties – about 40% below comparable US biotech valuations for a similar-stage asset.

The bridging study confirmed the efficacy signal. The program is now in Phase 3 globally. The company estimates they saved 3 years and $200M+ in development costs compared to building internally.

Conclusion

The China biotech licensing wave represents a structural shift in global pharma deal-making. Chinese biotechs are producing genuinely differentiated molecules, and the combination of domestic funding pressure and Western pipeline gaps is driving record deal volumes.

For Western BD teams, success requires adapting due diligence processes to address IP, clinical data translatability, manufacturing, and geopolitical risk. Teams that build this capability access high-value assets at lower valuations than comparable Western programs.

Explore related deal intelligence topics. Learn about biotech licensing deal structures and how NPV modeling applies to cross-border deals.

Frequently Asked Questions

The China Licensing Wave: Strategic Implications for Non-Chinese Biotech Companies

The China licensing wave creates competitive challenges for smaller Western biotechs. When a major pharma company in-licenses a Chinese Phase 2 asset in the same mechanism class or indication as a small US biotech’s own programme, that biotech faces a competitive headwind: the large pharma will run a much larger Phase 3 trial, will have more global development resources, and will likely reach the market first. Small biotechs in competitive mechanism classes should actively monitor Chinese biotech conference presentations and clinical trial registrations to identify incoming competition 12-18 months before Western announcements.

How to Evaluate a Chinese Biotech’s Regulatory Pathway to the US Market

For a Western company evaluating a Chinese asset for in-licensing, the regulatory pathway to FDA approval is the most critical risk factor. Four questions determine regulatory risk. First, was the pivotal trial conducted with US-representative patients? FDA requires that patient demographics reasonably reflect US patients. Second, is the manufacturing site FDA-inspectable? FDA inspections of Chinese manufacturing sites are ongoing but have faced COVID-era backlogs. Third, does the IND exist or will one need to be filed? Filing a new IND adds 12-18 months to the development timeline. Fourth, has FDA provided specific guidance on the indication regarding China-only trial data acceptability? Checking the precedent for your specific indication avoids surprises at NDA review.